Drugs / PB006
PB006
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04115488 | Oct 2019 → Aug 2021 | relapsing-remitting multiple sclerosis | Polpharma Biologics S.A. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PB006 | “Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment.” PMID 36689214 ↗ Mar 2023 |
| Known as | biosim-NTZ | “Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment.” PMID 36689214 ↗ Mar 2023 |
| Known as | natalizumab | “Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment.” PMID 36689214 ↗ Mar 2023 |
| Modality | Monoclonal antibody | “Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment.” PMID 36689214 ↗ Mar 2023 |